Lenzing Biocel Paskov's total assets reached CZK 7,358 mil at the end of 2019, down 0.049% compared to the previous year.
Current assets amounted to CZK 33,612 mil, or 457% of total assets while cash stood at CZK 1,585 mil at the end of 2019.
By contrast, total debt reached CZK 0 mil at the year-end, or 0% of total assets, while the firm's equity amounted to CZK 6,303 mil. As a result, net debt stood at CZK -1,587 mil at the end of 2019 and accounted for -25.2% of equity.
Net debt against equity is down 104 pp from five years ago (78.8%). The ratio against EBITDA decreased from 1.65x seen in 2014 to -0.819x.
The company’s cost of funding amounted to in 2019, down 3.62 pp compared to the average over the last 5 years.
You can see all the company’s data at Lenzing Biocel Paskov profile, or you can download a report on the company in the report section.
Helgi Library 
